Axa S.A. Sells 121,800 Shares of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)

Axa S.A. lowered its holdings in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) by 24.6% in the 2nd quarter, Holdings Channel reports. The firm owned 372,800 shares of the software maker’s stock after selling 121,800 shares during the period. Axa S.A.’s holdings in Allscripts Healthcare Solutions were worth $6,901,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of MDRX. Dimensional Fund Advisors LP increased its position in Allscripts Healthcare Solutions by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 11,003,259 shares of the software maker’s stock valued at $165,050,000 after acquiring an additional 63,724 shares during the last quarter. JPMorgan Chase & Co. increased its position in Allscripts Healthcare Solutions by 23.7% during the second quarter. JPMorgan Chase & Co. now owns 3,636,410 shares of the software maker’s stock valued at $67,310,000 after acquiring an additional 697,012 shares during the last quarter. Geode Capital Management LLC increased its position in Allscripts Healthcare Solutions by 3.5% during the first quarter. Geode Capital Management LLC now owns 2,910,477 shares of the software maker’s stock valued at $43,700,000 after acquiring an additional 97,946 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Allscripts Healthcare Solutions in the first quarter worth about $16,211,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Allscripts Healthcare Solutions by 41.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,074,481 shares of the software maker’s stock worth $16,133,000 after buying an additional 312,183 shares in the last quarter.

Shares of Allscripts Healthcare Solutions stock opened at $13.93 on Thursday. The stock has a 50 day moving average of $14.97 and a 200 day moving average of $16.29. Allscripts Healthcare Solutions, Inc. has a 12 month low of $9.56 and a 12 month high of $19.00. The firm has a market cap of $1.74 billion, a PE ratio of 2.77, a PEG ratio of 2.63 and a beta of 1.03. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.30.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last announced its quarterly earnings results on Wednesday, August 4th. The software maker reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. The company had revenue of $373.70 million during the quarter, compared to analyst estimates of $372.51 million. Allscripts Healthcare Solutions had a return on equity of 7.06% and a net margin of 49.61%. As a group, equities research analysts forecast that Allscripts Healthcare Solutions, Inc. will post 0.56 earnings per share for the current fiscal year.

In other news, Director Greg Garrison sold 77,381 shares of the firm’s stock in a transaction that occurred on Tuesday, September 7th. The stock was sold at an average price of $15.02, for a total value of $1,162,262.62. Following the completion of the sale, the director now directly owns 47,813 shares of the company’s stock, valued at approximately $718,151.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lisa Khorey sold 50,000 shares of the stock in a transaction that occurred on Thursday, August 5th. The stock was sold at an average price of $17.14, for a total value of $857,000.00. The disclosure for this sale can be found here. 1.91% of the stock is owned by company insiders.

A number of analysts have commented on the company. Canaccord Genuity restated a “buy” rating and issued a $18.00 price target on shares of Allscripts Healthcare Solutions in a research report on Friday, September 17th. Royal Bank of Canada upped their price objective on Allscripts Healthcare Solutions from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, August 6th. SVB Leerink upped their price objective on Allscripts Healthcare Solutions from $17.00 to $19.00 and gave the stock a “market perform” rating in a research note on Friday, August 6th. Zacks Investment Research lowered Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating and set a $19.00 price objective for the company. in a research note on Friday, July 16th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $17.00 price objective (up previously from $15.00) on shares of Allscripts Healthcare Solutions in a research note on Friday, August 6th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Allscripts Healthcare Solutions currently has a consensus rating of “Hold” and an average target price of $16.05.

Allscripts Healthcare Solutions Profile

Allscripts Healthcare Solutions, Inc engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segment. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units.

Featured Story: What are the advantages of the Stochastic Momentum Index?

Want to see what other hedge funds are holding MDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX).

Institutional Ownership by Quarter for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.